Ingemar Turesson
- Hematology top 0.05%
- Molecular Biology top 1%
- Oncology top 0.5%
- Genetics top 0.5%
- Pathology and Forensic Medicine top 1%
- Co-authors
- Ola LandgrenSigurður Y. KristinssonMagnus BjörkholmLynn R. GoldinJan WestinCecilie BlimarkUlf‐Henrik MellqvistBrian G.M. Durie
- Topics
- Multiple Myeloma Research and Treatments (97 papers)Chronic Lymphocytic Leukemia Research (36 papers)Cancer Treatment and Pharmacology (27 papers)
- Cited by
- HematologyGeneticsOncology
- Partner nations
- SwedenUnited StatesIceland
In The Last Decade
Ingemar Turesson
144 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Hematology 6.2k
- Molecular Biology 4.0k
- Oncology 3.5k
- Genetics 1.8k
- Pathology and Forensic Medicine 860
Countries citing papers authored by Ingemar Turesson
This map shows the geographic impact of Ingemar Turesson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingemar Turesson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingemar Turesson more than expected).
Fields of papers citing papers by Ingemar Turesson
This network shows the impact of papers produced by Ingemar Turesson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingemar Turesson. The network helps show where Ingemar Turesson may publish in the future.
Co-authorship network of co-authors of Ingemar Turesson
This figure shows the co-authorship network connecting the top 25 collaborators of Ingemar Turesson. A scholar is included among the top collaborators of Ingemar Turesson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingemar Turesson. Ingemar Turesson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 1 | |
| 3 | 3 | |
| 4 | 11 | |
| 5 | 4 | |
| 6 | 7 | |
| 7 | 1 | |
| 8 | 2 | |
| 9 | 124 | |
| 10 | 12 | |
| 11 | 179 | |
| 12 | 93 | |
| 13 | 101 | |
| 14 | 24 | |
| 15 | A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity | 16 |
| 16 | 99 | |
| 17 | 45 | |
| 18 | Involvement and intrinsic deficiencies of hematopoietic stem cells in MDS patients with trisomy 8 | 2 |
| 19 | 203 | |
| 20 | 2 |
About Ingemar Turesson
Ingemar Turesson is a scholar working on Hematology, Genetics and Oncology, having authored 148 papers that have together received 8.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (97 papers), Chronic Lymphocytic Leukemia Research (36 papers) and Cancer Treatment and Pharmacology (27 papers). The work is most often cited by research in Hematology (6.2k citations), Genetics (1.8k citations) and Oncology (3.5k citations). Ingemar Turesson has collaborated with scholars based in Sweden, United States and Iceland. Frequent co-authors include Ola Landgren, Sigurður Y. Kristinsson, Magnus Björkholm, Lynn R. Goldin, Jan Westin, Cecilie Blimark, Ulf‐Henrik Mellqvist, Brian G.M. Durie, Kazuyuki Shimizu and Gareth J. Morgan. Their work appears in journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.